- Conditions
- Influenza, Seasonal Influenza
- Interventions
- VRC-GENADJ0110-AP-NV (Adjuplex), Flucelvax, VRC-FLUMOS0111-00-VP (FluMos-v1)
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1225–1234
of 1,234
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Solid Tumor
- Interventions
- NeoTCR-P1 adoptive cell therapy, nivolumab, IL-2
- Biological
- Lead sponsor
- PACT Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 9
- States / cities
- Duarte, California • Los Angeles, California • Orange, California + 6 more
- Conditions
- Solid Tumor, Adult
- Interventions
- CX-801, pembrolizumab
- Drug
- Lead sponsor
- CytomX Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Englewood, Colorado • Pittsburgh, Pennsylvania + 2 more
- Conditions
- Advanced Solid Tumors, Metastatic Pancreatic Cancer, Pediatric Solid Tumor, Advanced Breast Cancer, Malignant Peripheral Nerve Sheath Tumor, Colorectal Neoplasms
- Interventions
- Metarrestin
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years to 120 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 2
- States / cities
- Fairway, Kansas • Bethesda, Maryland
- Conditions
- LMNA-Related Dilated Cardiomyopathy
- Interventions
- NVC-001 - Low Dose, NVC-001 - Intermediate Dose, NVC-001 - High Dose
- Genetic
- Lead sponsor
- Nuevocor Pte. Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 5 more
- Conditions
- Advanced Solid Tumors
- Interventions
- VBC108
- Drug
- Lead sponsor
- VelaVigo Bio Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 5
- States / cities
- Duarte, California • Grand Rapids, Michigan • New York, New York + 2 more
- Conditions
- Respiratory Tract Infection
- Interventions
- Formulation A, Formulation B, Formulation C, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 317 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- South Miami, Florida • Peoria, Illinois • Fremont, Nebraska + 1 more
- Conditions
- Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer, High-Grade Serous Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer
- Interventions
- Azirkitug, Budigalimab, Bevacizumab, Telisotuzumab Adizutecan
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 694 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 20
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 15 more
- Conditions
- Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer, Advanced Pancreatic Ductal Adenocarcinoma, Advanced Gastric Cancer, Advanced Gastroesophageal Junction Cancer, Advanced Esophageal Adenocarcinoma
- Interventions
- BGB-53038, Tislelizumab, Cetuximab
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Kansas City, Kansas • Baltimore, Maryland + 1 more
- Conditions
- Virus Diseases
- Interventions
- 1 µg CoV2 SAM (LNP)
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, New York